Replies to post #32302 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Academic information
Location: Home > Text

Prof. ODIDI Isa, Chief Scientist, Intellipharmaceutics Inc., Canada

Time: 2018-01-09 Author: Yang Jianjun Views: Article Source:


Title: Formulation Innovation and New Technologies: 505 (b) 2 regulatory pathway

Report Time: January 10, 2018 (Wednesday) 15: 10-16: 10
Report Location: South Campus. Fourth Teaching Building 103
Speaker : Prof. ODIDI Isa (CEO, Chairman, Founder and Chief Scientist of Intellipharmaceutics Inc., Canada)
Organizer: School of Pharmacy
Endless academy
Graduate School (Discipline Construction Office)
Liaoning Province graduate modern medicine field innovation and exchange center
Liaoning Province Pharmaceutical Preparation Engineering Center
Listen to the Wisdom Forum to broaden the academic horizons
Welcome teachers and students to participate actively!

Speaker Profile:

1995-1998, Biovail Corporation (Canadian pharmaceutical company Bayer International) as chief scientist, research director, and corporate vice president. In 1995, Dr. Odidi was invited by the Canadian government to serve as R & D Director for start-up pharmaceutical company Bayer International. Dr. Odidi submitted a Canadian pharmaceutical company's first generic controlled-release drug in the US FDA, and later declared a Canadian drug company's first controlled-release new drug in the United States FDA according to 505 (b) 2 Modified New Drug Path. . Within just 3 years, Dr. Odidi led the R & D team to successfully develop over 10 modified controlled-release new drugs and generic drugs, and successively obtained the approval from the U.S. FDA. Among them, the annual sales of three heavy-weight drugs exceeded 1 billion U.S. dollars. In 1997, Thirteen Israel acquired exclusive rights to sell all controlled release pharmaceutical products from Biovail. In 2001, Biovail received $ 570 million in sales profits, making it Canada's largest pharmaceutical company at that time with a market capitalization of more than $ 7.2 billion.

1999-present, Intellipharmaceutics Inc. (CEO), CEO, Chairman, Founder and Chief Scientist. In the early days of Canadian Smart Pharma, Biovail developed its proprietary controlled release drug as an exclusive R & D partner for Biovail. Since then, many of the world's top 50 pharmaceutical companies have commissioned Clever Pharma to develop controlled and controlled release pharmaceutical products such as Teva, GSK, Par and Mallinckrodt. One of the world's top 500 biopharmaceuticals, Cleveland Canada has filed 12 drugs with the U.S. FDA, including two new modified controlled-release drugs and 10 controlled-release generic drugs. Clever Canada is the North American pharmaceutical companies in the United States FDA has a controlled release of the largest drug companies.

2017.05-present, Smart Pharmaceutical (Shanghai) Co., Ltd. was established as Chairman, Founder and Chief Scientist.
Dr. Odidy has 30 approved patents and over 100 pending patents in the United States, Canada, EU, China, India and Japan. There are already over 100 patents in the world that cite the technology of theodidi. For the North American market, Dr. Odidi and his wife, Dr. Amina, have developed 55 controlled-release drugs through their independent intellectual property R & D platform. The couple are the largest group in the history of the FDA to apply for oral controlled-release drugs with the most FDA-approved International famous pharmaceutical scientist.

Dr. Odidi is a world-class scientist and recognized as a prolific inventor in the fields of pharmacy, pharmacy research, drug development, pharmaceutical production and pharmaceutical technology. He is reputed as a pioneer of innovations in drug delivery such as controlled release, extended release, modified release, targeted release and timed release. He brings these innovative technologies to market and commercializes them, making a significant contribution to the pharmaceutical industry in Canada and the United States.


Next: Professor Peng Jinyong Dalian Medical University to our school for academic exchanges

[bluelucky]

Whether smart Pharma is owned by Odidi or intelli it is an affiliate of intelli as the controlling parties are related.

If it was set up in may it should have been disclosed by intelli.

Intelli needs to address this issue ASAP.